Next expected deadline: TBD

Value & Term

Up to $200,000 for up to a maximum of 18 months

What is the Alberta/Pfizer Translational Research Fund Opportunity?

The Alberta/Pfizer Translational Research Fund Opportunity is a partnership between Pfizer Canada Inc. (Pfizer), Alberta Innovates – Health Solutions (AIHS), Alberta’s Ministry of Innovation and Advanced Education (IAE), and Western Economic Diversification (WD) Canada. This partnership will provide opportunities to focus on the development and commercialization of innovations in health.

What are the objectives of the Alberta/Pfizer Translational Research Fund?

The Alberta/Pfizer Translational Research Fund Opportunity supports innovative translational research activities in areas of unmet health or health system needs with strong potential for technology transfer and commercialization over the short or medium term (two to five years). The Opportunity will support the development and commercialization of innovations in priority areas identified by Pfizer and the province of Alberta (see sidebar).

Preference will be given to research projects focused on the discovery and development of novel therapeutic targets and compounds in the creation of new knowledge and its potential transfer to use (commercialization) in the priority topic areas described (see sidebar).

What opportunity does the Alberta/Pfizer Translational Research Fund provide?

Translational research grants will be offered for a maximum of 18 months and for a maximum amount of $200,000. Payments of the grants will be based on an agreed upon set of objectives and milestones and the submission of periodic reports outlining progress towards the expected objectives/milestones.

Eligible expenses include:

    • Salaries of research personnel essential to the project (excluding salaries of the principal investigator, and co-principal investigator(s), if applicable), including the support of graduate and post-graduate trainees,
    • Purchase and/or leasing of equipment required and justified in the proposal for funding.
    • Research material (including cost for access to data) required for the research project.

How do I apply?

The application process for the Alberta/Pfizer Translational Research Fund Opportunity is a two phase process consisting of a Letter of Intent (Phase 1) and a Full Application (Phase 2).

Important: Please review the Alberta/Pfizer Translational Research Fund Opportunity Program Guide (2013/2014) before applying.

What is the review process?

A review committee will be appointed by AIHS based on recommendations from the Alberta/Pfizer Translational Research Fund Steering Committee. The review committee will bring a proven track record of scientific discourse, technology transfer as well as pharmaceutical R&D and commercialization expertise to assess the proposals. The review committee may solicit additional scientific review or relevant advice by external expert reviewers.

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Share on LinkedIn

For more information:
Mike Christen, Officer, Grants Processing
Mike.Christen@albertainnovates.ca
(780) 809-2557

Quick Downloads

 

Recent Decisions

10/01/2014
November 2013 Alberta/ Pfizer – Full Application »

23/09/2013
July 2013 Alberta/Pfizer – Letter of Intent »

01/10/2012
June 2012 Alberta/Pfizer Translational Research Fund Opportunity – Full Application »

01/05/2012
March 2012 Alberta/Pfizer Translational Research Fund Opportunity – Letter of Intent »

View more recent decisions »

Priority topic areas:

  • Neuroscience/ Alzheimer’s Disease/ neurodegeneration/ neurological diseases
  • Pain and sensory disorders
  • Immunology and autoimmunity
  • Inflammation and remodeling
  • Diabetes and cardiovascular or other chronic disease issues as they relate to the consequences of diabetes
  • Targeted chemotherapy (e.g., novel antibody or antibody-drug conjugates) or cutting edge epigenetic targets in oncology
  • Orphan and genetic diseases
  • Other disease areas and technologies may also be considered based on the potential for commercialization.

Information Sessions

Sorry, there are no upcoming events.